Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $731,769.92 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 13,334 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at $4,507,788.32. This trade represents a 13.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Janux Therapeutics Stock Up 1.3 %

Shares of JANX stock opened at $53.92 on Friday. Janux Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $71.71. The firm has a fifty day moving average of $54.53 and a 200-day moving average of $47.88. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of -46.09 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm’s quarterly revenue was down 82.6% compared to the same quarter last year. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. increased its stake in Janux Therapeutics by 64.5% in the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock valued at $937,000 after buying an additional 7,442 shares during the last quarter. Virtu Financial LLC grew its holdings in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Janux Therapeutics in the third quarter valued at about $940,000. Geode Capital Management LLC raised its holdings in Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after acquiring an additional 38,490 shares in the last quarter. Finally, Barclays PLC raised its holdings in Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock worth $7,907,000 after acquiring an additional 144,883 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, December 3rd. Stifel Nicolaus raised their price target on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Leerink Partners upped their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Scotiabank raised their target price on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 4th. Finally, BTIG Research boosted their target price on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.